Octant Raises $80 Million Series B Round to Support Expansion of Next-Generation Drug Discovery Platform, Announces Collaboration with Bristol Myers Squibb and Key AppointmentsBusiness Wire • 04/21/22
Veeva Vault CTMS Launched at Bristol Myers Squibb to Simplify Clinical Trial Processes GloballyPRNewsWire • 04/21/22
EDP Renewables and Bristol Myers Squibb Execute Power Purchase Agreement for the Cattlemen Solar ParkGlobeNewsWire • 04/21/22
Nektar, Bristol Myers Squibb end clinical development of combination therapy including OpdivoMarket Watch • 04/18/22
Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab)PRNewsWire • 04/14/22
Neoadjuvant Opdivo (nivolumab) with Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 TrialBusiness Wire • 04/11/22
Bristol Myers Squibb Foundation Honors Diversity and Health Equity Leader By Naming Diversity in Clinical Trials Training Program After Him; Welcomes Gilead Sciences as Program SupporterBusiness Wire • 04/11/22
Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Certain Forms of Relapsed or Refractory Large B-cell LymphomaBusiness Wire • 04/05/22
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as First-Line Treatment for Patients with.Business Wire • 04/05/22